- Ofatumumab - new and different monoclonal anti-CD20 antibody in the treatment of multiple sclerosis2021 | Second Faculty of Medicine
- Capabilities to modulate inflammation in patients suffering from multiple sclerosis by biologics targeting CD20 molecule on mature B cells are expanding2020 | Faculty of Medicine in Hradec Králové
- 2020 AAN Highlights Long-term data on efficacy of CD20+depletion B-cells in the treatment of MS2020 | First Faculty of Medicine
- Biologics targeting CD20 molecule on B cells in the therapy of multiple sclerosis patients2022 | Faculty of Medicine in Hradec Králové
- Ocrelizumab is highly effective in the treatment of multiple sclerosis. What is the immunobiological background of its clinical effectivity?2020 | Faculty of Medicine in Hradec Králové
- B lymphocytes in cerebrospinal multiple sclerosis and the role of a B lymphocyte-targeting biologic agent in its therapy2018 | Faculty of Medicine in Hradec Králové
- Ofatumumab2011 | Faculty of Medicine in Hradec Králové
- Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20(+) Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma2012 | First Faculty of Medicine
- Current application of ritusimab in pharmacotherapy2015 | Publication without faculty affiliation
- Rituximab and its indications2019 | Publication without faculty affiliation
- Radioimmunotherapy in Patients with Relapsed or Refractory CD20+ non-Hodgkin´s Lymphoma +32006 | Publication without faculty affiliation
- Radioimunotherapy ytrium-90 (90Y)-ibritumomab tiuxetanam in patients with folicular non-hodgkin lymphoma – experience of one departmen2010 | First Faculty of Medicine
- Selective Depletion of CD20+ B Cells with A Single Course of Rituximab: Pronouced and Sustained Benefits for up to 48 Weeks in Patiens with Rheumatoid ArthritisPublication without faculty affiliation
- Radioimmunotherapy with 90Y-radiolabelled anti-CD20 monoclonal antibody in patients with B-cell non-Hodgkin´s lymphoma +2Publication without faculty affiliation
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia2010 | First Faculty of Medicine, Third Faculty of Medicine
- B cells as an integral part of harmful inflammation in multiple sclerosis and affecting them with anti-CD20 therapy2017 | Faculty of Medicine in Hradec Králové
- Ocrelizumab - pharmacoloical profile2018 | Faculty of Medicine in Pilsen
- Komentář k článku Denzita exprese antigenu CD20 na populaci nádorových buněk u pacientů s chornickými lymfoproliferacemi B-lymfocytární řady2006 | First Faculty of Medicine
- Prognostic factors and markers of activity in multiple myeloma2000 | First Faculty of Medicine
- Anti CD20 Antibody (Rituximab) Therapy Leads to High Molecular Remission Rate with Favourable Outcome in Patients with Non-Hodgkin's LymphomaPublication without faculty affiliation
- Anti CD20 Antibody (Rituximab) Therapy Leads to High Molecular Remission Rate with Favourable Outcome in Patients with Non-Hodgkin's Lymphoma2001 | Faculty of Physical Education and Sport
- Prognostic factors and markers of activity in multiple myeloma: Results of the Cooperative Group for Diagnostic and Treatment of Multiple Myeloma2000 | First Faculty of Medicine
- Immuno chemotherapy (anti CD20 and fludarabin/cyclophosphamide) and high dose chemotherapy with ASCT increases molecular remission rate but cannot pretend relapsesPublication without faculty affiliation
- Immuno chemotherapy (Anti CD20 and Fludarabin/Cyclophosphamide) and high dose chemotherapy with ASCT increases molecular remission rate but cannot prevent relapsesPublication without faculty affiliation
- The role of rituximab maintenance in elderly patients with mantle cell lymphoma in first remission - single centre experience2015 | Faculty of Medicine in Pilsen